{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:23:55Z","timestamp":1790774635359,"version":"4.1.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T00:00:00Z","timestamp":1776470400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003768","name":"Universit\u00e9 de Strasbourg","doi-asserted-by":"publisher","award":["ANR-10-IDEX-0002"],"award-info":[{"award-number":["ANR-10-IDEX-0002"]}],"id":[{"id":"10.13039\/501100003768","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003768","name":"Universit\u00e9 de Strasbourg","doi-asserted-by":"publisher","award":["ANR-20-SFRI-0012"],"award-info":[{"award-number":["ANR-20-SFRI-0012"]}],"id":[{"id":"10.13039\/501100003768","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002915","name":"Fondation pour la Recherche M\u00e9dicale","doi-asserted-by":"publisher","award":["SPF202409019620"],"award-info":[{"award-number":["SPF202409019620"]}],"id":[{"id":"10.13039\/501100002915","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010663","name":"H2020 European Research Council","doi-asserted-by":"publisher","award":["950101"],"award-info":[{"award-number":["950101"]}],"id":[{"id":"10.13039\/100010663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004794","name":"Centre National de la Recherche Scientifique","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100016037","name":"Fondation Gustave Roussy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016037","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004099","name":"Ligue Contre le Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jconrel.2026.114941","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T23:15:51Z","timestamp":1776467751000},"page":"114941","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Engineering the subcutaneous delivery of antibody-drug conjugates"],"prefix":"10.1016","volume":"395","author":[{"given":"Alexandre","family":"Detappe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Guti\u00e9rrez-Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Pivot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2026.114941_bb0005","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s40259-018-0295-0","article-title":"Subcutaneous administration of biotherapeutics: an overview of current challenges and opportunities","volume":"32","author":"Bittner","year":"2018","journal-title":"BioDrugs"},{"key":"10.1016\/j.jconrel.2026.114941_bb0010","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S1470-2045(20)30536-2","article-title":"FeDeriCa study group, Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study","volume":"22","author":"Tan","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jconrel.2026.114941_bb0015","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1007\/s12325-017-0612-x","article-title":"Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience","volume":"34","author":"Salles","year":"2017","journal-title":"Adv. Ther."},{"key":"10.1016\/j.jconrel.2026.114941_bb0020","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/S1470-2045(13)70383-8","article-title":"PrefHer Study Group, Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study","volume":"14","author":"Pivot","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jconrel.2026.114941_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2024.118010","article-title":"The journey of antibody-drug conjugates for revolutionizing cancer therapy: a review","volume":"117","author":"Akram","year":"2025","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.jconrel.2026.114941_bb0030","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","article-title":"DESTINY-Breast03 trial investigators, trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer","volume":"386","author":"Cort\u00e9s","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2026.114941_bb0035","doi-asserted-by":"crossref","first-page":"4361","DOI":"10.1039\/C8CS00676H","article-title":"Cleavable linkers in antibody\u2013drug conjugates","volume":"48","author":"Bargh","year":"2019","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.jconrel.2026.114941_bb0040","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nrd.2016.268","article-title":"Strategies and challenges for the next generation of antibody-drug conjugates","volume":"16","author":"Beck","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2026.114941_bb0045","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","article-title":"Unlocking the potential of antibody-drug conjugates for cancer therapy","volume":"18","author":"Drago","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2026.114941_bb0050","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1007\/s12094-017-1684-4","article-title":"Cost minimization analysis of treatment with intravenous or subcutaneous trastuzumab in patients with HER2-positive breast cancer in Spain","volume":"19","author":"Lopez-Vivanco","year":"2017","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.jconrel.2026.114941_bb0055","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1080\/10717544.2018.1551442","article-title":"ENHANZE\u00ae drug delivery technology: a novel approach to subcutaneous administration using recombinant human hyaluronidase PH20","volume":"26","author":"Locke","year":"2019","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jconrel.2026.114941_bb0060","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1517\/17425247.4.4.427","article-title":"Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration","volume":"4","author":"Frost","year":"2007","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2026.114941_bb0065","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202511918","article-title":"High concentration antibody formulations enabled via thermostable ionic liquids","author":"Erdi","year":"2026","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2026.114941_bb0070","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2205540","article-title":"A systematic review of commercial high concentration antibody drug products approved in the US: formulation composition, dosage form design and primary packaging considerations","volume":"15","author":"Ghosh","year":"2023","journal-title":"MAbs"},{"key":"10.1016\/j.jconrel.2026.114941_bb0075","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/jps.20079","article-title":"Challenges in the development of high protein concentration formulations","volume":"93","author":"Shire","year":"2004","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2026.114941_bb0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1152\/physrev.1993.73.1.1","article-title":"Interstitial-lymphatic mechanisms in the control of extracellular fluid volume","volume":"73","author":"Aukland","year":"1993","journal-title":"Physiol. Rev."},{"issue":"Suppl. 1","key":"10.1016\/j.jconrel.2026.114941_bb0085","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/S0151-9638(10)70007-7","article-title":"Hyaluronic acid: structure, metabolism and implication in cicatrisation","volume":"137","author":"Gall","year":"2010","journal-title":"Ann. Dermatol. Venereol."},{"key":"10.1016\/j.jconrel.2026.114941_bb0090","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s10928-020-09691-3","article-title":"Predicting monoclonal antibody pharmacokinetics following subcutaneous administration via whole-body physiologically-based modeling","volume":"47","author":"Hu","year":"2020","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.jconrel.2026.114941_bb0095","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(01)00150-8","article-title":"The physiology of the lymphatic system","volume":"50","author":"Swartz","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2026.114941_bb0100","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.3390\/pharmaceutics15041132","article-title":"Pharmacokinetics and pharmacodynamics of antibody-drug conjugates administered via subcutaneous and intratumoral routes","volume":"15","author":"Chang","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2026.114941_bb0105","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1038\/nbt.2968","article-title":"Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates","volume":"32","author":"Lyon","year":"2014","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2026.114941_bb0110","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.ejpb.2017.06.029","article-title":"High-concentration protein formulations: how high is high?","volume":"119","author":"Garidel","year":"2017","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2026.114941_bb0115","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1016\/j.xphs.2021.03.017","article-title":"A review of formulations of commercially available antibodies","volume":"110","author":"Strickley","year":"2021","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2026.114941_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2023.115249","article-title":"Stability assessment of Polatuzumab vedotin and Brentuximab vedotin using different analytical techniques","volume":"228","author":"Mohamed","year":"2023","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jconrel.2026.114941_bb0125","doi-asserted-by":"crossref","first-page":"9161","DOI":"10.1021\/acs.jmedchem.3c00794","article-title":"Optimization of drug-linker to enable long-term storage of antibody-drug conjugate for subcutaneous dosing","volume":"66","author":"Hobson","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2026.114941_bb0130","first-page":"33","article-title":"Antibody conjugation and formulation","volume":"2","author":"Alves","year":"2019","journal-title":"Antib. Ther."},{"key":"10.1016\/j.jconrel.2026.114941_bb0135","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1021\/bc5004982","article-title":"Site-specific antibody-drug conjugates: the nexus of bioorthogonal chemistry, protein engineering, and drug development","volume":"26","author":"Agarwal","year":"2015","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2026.114941_bb0140","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1021\/mp5000218","article-title":"Specific decrease in solution viscosity of antibodies by arginine for therapeutic formulations","volume":"11","author":"Inoue","year":"2014","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2026.114941_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.molliq.2022.120349","article-title":"The influence of excipients on the viscosity of monoclonal antibody solutions","volume":"366","author":"Hribar-Lee","year":"2022","journal-title":"J. Mol. Liq."},{"key":"10.1016\/j.jconrel.2026.114941_bb0150","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.addr.2008.02.011","article-title":"Cyclodextrin-based supramolecular architectures: syntheses, structures, and applications for drug and gene delivery","volume":"60","author":"Li","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2026.114941_bb0155","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.3390\/biomedicines11113080","article-title":"Lysosomal-cleavable peptide linkers in antibody-drug conjugates","volume":"11","author":"Balamkundu","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.jconrel.2026.114941_bb0160","first-page":"33","article-title":"Antibody-drug conjugates: recent advances in conjugation and linker chemistries, protein","volume":"9","author":"Tsuchikama","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2026.114941_bb0165","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.jconrel.2015.09.032","article-title":"Stabilization of cysteine-linked antibody drug conjugates with N-aryl maleimides","volume":"220","author":"Christie","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.114941_bb0170","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/nbt.1480","article-title":"Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index","volume":"26","author":"Junutula","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2026.114941_bb0175","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/j.apsb.2020.04.012","article-title":"Recent advances of antibody drug conjugates for clinical applications","volume":"10","author":"Zhao","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.jconrel.2026.114941_bb0180","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.ijpharm.2018.10.008","article-title":"Polysorbate degradation in biotherapeutic formulations: identification and discussion of current root causes","volume":"552","author":"Dwivedi","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2026.114941_bb0185","article-title":"Subcutaneous administration of a Zwitterionic Chitosan-based hydrogel for controlled spatiotemporal release of monoclonal antibodies","volume":"36","author":"Gr\u00e9a","year":"2024","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2026.114941_bb0190","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.201801147","article-title":"A biocompatible therapeutic catheter-deliverable hydrogel for in situ tissue engineering","volume":"8","author":"Steele","year":"2019","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.jconrel.2026.114941_bb0195","doi-asserted-by":"crossref","first-page":"4430","DOI":"10.1021\/acs.biomac.9b01129","article-title":"Injectable polymer-nanoparticle hydrogels for local immune cell recruitment","volume":"20","author":"Fenton","year":"2019","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.jconrel.2026.114941_bb0200","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1021\/acs.biomac.0c00895","article-title":"Environment controls biomolecule release from dynamic covalent hydrogels","volume":"22","author":"Marco-Dufort","year":"2021","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.jconrel.2026.114941_bb0205","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abd7563","article-title":"Protein-avoidant ionic liquid (PAIL)-coated nanoparticles to increase bloodstream circulation and drive biodistribution","volume":"6","author":"Hamadani","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.jconrel.2026.114941_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2026.114800","article-title":"Challenging the myths of subcutaneous delivery: an industry expert perspective","volume":"393","author":"Bittner","year":"2026","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.114941_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2024.115301","article-title":"Towards more tolerable subcutaneous administration: review of contributing factors for improving combination product design","volume":"209","author":"Mathias","year":"2024","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2026.114941_bb0220","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2024.2402713","article-title":"Navigating large-volume subcutaneous injections of biopharmaceuticals: a systematic review of clinical pipelines and approved products","volume":"16","author":"Green","year":"2024","journal-title":"mAbs"},{"key":"10.1016\/j.jconrel.2026.114941_bb0225","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40495-026-00442-5","article-title":"Subcutaneous administration of antibody-drug conjugates","volume":"12","author":"Yaseen","year":"2026","journal-title":"Curr. Pharmacol. Rep."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926003445?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926003445?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T09:14:58Z","timestamp":1781255698000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365926003445"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":45,"alternative-id":["S0168365926003445"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.114941","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Engineering the subcutaneous delivery of antibody-drug conjugates","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.114941","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"114941"}}